<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Wolfson Brain Imaging Centre</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5EE55E7A-9A75-4570-A04D-D9F36C3129EC"><gtr:id>5EE55E7A-9A75-4570-A04D-D9F36C3129EC</gtr:id><gtr:name>National Institutes of Health</gtr:name><gtr:address><gtr:line1>31 Center Drive</gtr:line1><gtr:line2>9000 Rockville Pike</gtr:line2><gtr:postCode>20892</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9B520E8D-05F2-4A18-9EDF-C1503366E9E1"><gtr:id>9B520E8D-05F2-4A18-9EDF-C1503366E9E1</gtr:id><gtr:name>Eli Lilly &amp; Company Ltd</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4E80443A-E7AA-4216-9492-FC8B1A583B53"><gtr:id>4E80443A-E7AA-4216-9492-FC8B1A583B53</gtr:id><gtr:firstName>Trevor</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Robbins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/654E5DB9-06ED-4316-B9B9-4DAC598FE9A7"><gtr:id>654E5DB9-06ED-4316-B9B9-4DAC598FE9A7</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:surname>Nestor</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/B7296B44-D98A-4E67-8053-E7E99D157D05"><gtr:id>B7296B44-D98A-4E67-8053-E7E99D157D05</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>Douglas</gtr:otherNames><gtr:surname>Pickard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/6C483069-8D3A-498D-8435-56F37F66DEBB"><gtr:id>6C483069-8D3A-498D-8435-56F37F66DEBB</gtr:id><gtr:firstName>Jean-Claude</gtr:firstName><gtr:surname>Baron</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/5638B83E-8513-4CEC-A4BD-0C0805F4A22C"><gtr:id>5638B83E-8513-4CEC-A4BD-0C0805F4A22C</gtr:id><gtr:firstName>Franklin</gtr:firstName><gtr:otherNames>Imo</gtr:otherNames><gtr:surname>Aigbirhio</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/FB718CC2-60A9-424C-874E-006BC98FFF1E"><gtr:id>FB718CC2-60A9-424C-874E-006BC98FFF1E</gtr:id><gtr:firstName>Jeffrey</gtr:firstName><gtr:otherNames>Wayne</gtr:otherNames><gtr:surname>Dalley</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0900903"><gtr:id>752DCD0E-96C1-4B88-AF55-31672643C715</gtr:id><gtr:title>Cambridge PET Neurochemist Training Programme</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0900903</gtr:grantReference><gtr:abstractText>Some radioactive molecules emit gamma radiation that can be detected outside the body and so when injected into humans and animals, in safe low levels, can be used to generate images, using sophisticated scanners, of the brain for biomedical research and clinical diagnosis. However, the molecules have to be designed to target the sites of the brain to be investigated, which is done by attaching a biological compound to the radioactive molecule to create products called radiopharmaceuticals. Due to the severe lack of scientists in the UK who have the specialised skills to design and prepare these radiopharmaceuticals we plan to recruit and train a scientist to join our multidisplicinary team. To achieve this we have created a bespoke training programme which will involve learning from researchers in academia and industry, who are either developing and/or using this imaging technology. As part of this training the scientist will help design new radiopharmaceuticals that would then be used in our on-going research programmes to understand the biological mechanisms of some major diseases and disorders of the brain, and thereby identify some possible treatments. For this specific programme we would be undertaking research projects on Alzheimer?s disease, depression, schizophrenia, obsessive compulsive disorder and drug addiction.</gtr:abstractText><gtr:technicalSummary>To address one of the major restrictions on the use of the molecular imaging technique of positron emission tomography (PET) for neuroscience research at Cambridge, the lack of trained PET chemists to design and prepare the required brain imaging probes, proposed is an integrated programme of training and research. In partnership with PET centres, academic and industrial, in the US and Europe we have constructed a training programme designed to train a post-doctoral scientist with a PhD background in chemistry to group leader capability within four yours. Integrated with this training, is the development of probes for the 5-HT2a receptors and beta-amyloid plaques and in the second phase of the programme collaboration with Siemens in the development of novel imaging probes for neurofibrillary tangles, one of the main neuropathological features of Alzheimer s disease (AD) and other dementias. 
The tracers will then be applied to PET imaging projects in the area of neuropsychiatric and neurodegenerative disorders, with a focus on 1) preclinical studies that have significant translational aspects and 2) human research projects targeted toward understanding the mechanisms of neurological diseases and thereby identifying potential therapeutics. The proposed projects include; i) studies on impulsivity based on imaging 5-HT2a receptors on rats with this behavioural trait; ii) imaging serotonergic modulation in marmosets to investigate mechanistic components common to various neuropsychiatric disorders such of schizophrenia, depression and obsessive compulsive disorder; iii) the role of 5-HT2a in frontotemporal dementia and iv) evaluation of the novel beta-amyloid tracer in AD and MCI patients and normal control subjects, coupled with autoradiographic experiments on brain tissue.</gtr:technicalSummary><gtr:fund><gtr:end>2014-08-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-03-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>602098</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Cambridge Institute for Medical Research (CIMR)</gtr:department><gtr:description>Development of PET probes for imaging tau tangles</gtr:description><gtr:id>942FECD5-4980-4C50-AF1B-B9FD06AB0C2D</gtr:id><gtr:impact>result in award of grants. Details outlined further</gtr:impact><gtr:outcomeId>o2G7jmJww4W-1</gtr:outcomeId><gtr:partnerContribution>Experince in animal models of dementia and transgenic mice tissue</gtr:partnerContribution><gtr:piContribution>development of PET probes</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2010-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Eli Lilly &amp; Company Ltd</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>Avid Radiopharmaceuticals</gtr:department><gtr:description>Development and Application of Tau PET probes</gtr:description><gtr:id>FE7674D0-7AA6-486D-ACBF-49203EC6B63D</gtr:id><gtr:impact>on-going</gtr:impact><gtr:outcomeId>TCnNno8PPF1-1</gtr:outcomeId><gtr:partnerContribution>supply of novel chemicals and confidential information</gtr:partnerContribution><gtr:piContribution>Characterisation of novel PET tau radiotracers</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institutes of Health (NIH)</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>National Institute of Mental Health (NIMH)</gtr:department><gtr:description>Development of Novel PET Radiochemical methods</gtr:description><gtr:id>FD5D2218-2C57-4A66-88D2-2F26D66D058D</gtr:id><gtr:impact>publication: Riss PJ, Lu S, Telu S, Aigbirhio FI, Pike VW. Cu(I)-catalyzed (11)C carboxylation of boronic acid esters: a rapid and convenient entry to (11)C-labeled carboxylic acids, esters, and amides. Angew Chem Int Ed Engl 2012; 51:2698-2702</gtr:impact><gtr:outcomeId>iweLpXF8KmZ-1</gtr:outcomeId><gtr:partnerContribution>Hosted the visiting postdoc with full and free access to their research facilities and training in advanced PET radiochemistry . 
 Also intellectual input into the project</gtr:partnerContribution><gtr:piContribution>Member of the research group , spent 5 months as a visiting scientist as part of project collaboration</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Physics at Work</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>062B15F1-5D67-4FBD-AF5F-820FA8A34449</gtr:id><gtr:impact>Talk of techniques used in department following by questions

N/A</gtr:impact><gtr:outcomeId>54623906c4a283.75330611</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Trust Multi-user equipment grant</gtr:description><gtr:end>2018-07-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:id>08421897-7859-4091-B7AD-5ABC0E0ABE66</gtr:id><gtr:outcomeId>A8RG7eRuaXX</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Development of a radioligand binding assay for</gtr:description><gtr:end>2013-03-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>ABCD2FC5-4553-4CB4-B824-0C8BD25D1EBE</gtr:id><gtr:outcomeId>FhqttuPAKQS0</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1537000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>NIHR, Biomedical Research Unit in Dementia Capital Funding</gtr:description><gtr:end>2012-02-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>184DE2DF-4493-41EA-86A7-1E82ECE19708</gtr:id><gtr:outcomeId>SP3SsVVYbYC</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>725000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>NIHR Cambridge Biomedical Research Centre</gtr:department><gtr:description>NIHR Biomedical Research Unit in Dementia</gtr:description><gtr:end>2017-03-02</gtr:end><gtr:fundingOrg>National Institute for Health Research</gtr:fundingOrg><gtr:id>33069D01-3166-4908-AF69-DD4997E2989A</gtr:id><gtr:outcomeId>GSD9yrq5ivn0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1016891</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Strategic grant</gtr:description><gtr:end>2017-10-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:fundingRef>MR/k02308X/1</gtr:fundingRef><gtr:id>47BAA0A2-6834-4ED5-994E-2835E4A27C11</gtr:id><gtr:outcomeId>ik47oanSVD5</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-11-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC MHRA PET Expert Panel</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>9F61800B-E689-4693-B14A-C468AEE92441</gtr:id><gtr:impact>Help and advising the UK PET community on the UK regulatory framework relating to medicines. Facilitate discussions between the PET community and the UK MHRA</gtr:impact><gtr:outcomeId>fCNU7Mqj4YT</gtr:outcomeId><gtr:type>Participation in advisory committee</gtr:type><gtr:url>http://www.mrc.ac.uk/research/facilities/mhra-mrc-pet-panel/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MRC PET Strategic Meeting</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>5CF276CF-C931-4FFF-A005-E981AA003EE0</gtr:id><gtr:impact>Increased level of PET neuroscience chemists in the UK</gtr:impact><gtr:outcomeId>N8uF7JKL9xj</gtr:outcomeId><gtr:type>Participation in a national consultation</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Novel compounds with high binding affinity to tau fibrils have been labelled with PET radioisotopes and have been shown to have good brain entry in animal models</gtr:description><gtr:id>8AE1C774-2E42-4A50-A82A-7E3AE8AF46A1</gtr:id><gtr:impact>This still under development</gtr:impact><gtr:outcomeId>o8LFgoVWx4k</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Novel PET Probe for imaging tau tangles</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Novel radiotracer for imaging the enzyme GSK-3 in vivo</gtr:description><gtr:id>8252A02D-E857-4793-B8F4-2173BD743F49</gtr:id><gtr:impact>Further characterisation of the radiotracer for application and then a joint publication</gtr:impact><gtr:outcomeId>56dd895948b6e2.11132175</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PET radiotracer for GSK-3</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.ncbi.nlm.nih.gov/pubmed/26005531</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>novel chemical compounds that bind to tau tangles for potential use as PET probes</gtr:description><gtr:id>4EFE703B-08F7-486E-948C-B74082D4FFE5</gtr:id><gtr:impact>enabled further grant funding</gtr:impact><gtr:outcomeId>mAzpJNzC6pU</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>tau compounds</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>The first fluorine-18 labelled positron emission tomography agonist radioligand for imaging opioid receptors</gtr:description><gtr:id>3E8232AC-2B1D-4D8B-AA9E-3FFB3C30DA9A</gtr:id><gtr:impact>Application for study opioid receptors in models of addictions</gtr:impact><gtr:outcomeId>P5aXRv2MZYq</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>A novel PET probe for imaging Opioid Receptors</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>54A37F3B-70F4-4C81-8C9E-058DB9A839DD</gtr:id><gtr:title>Diagnostic utility of amyloid PET in cerebral amyloid angiopathy-related symptomatic intracerebral hemorrhage.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6d7fb06edfb9f77f45f51b6c2af414e7"><gtr:id>6d7fb06edfb9f77f45f51b6c2af414e7</gtr:id><gtr:otherNames>Baron JC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>54621f397936e9.20403614</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8C2B78AE-B116-4B5A-8C0C-313611B5C876</gtr:id><gtr:title>Amyloid imaging with carbon 11-labeled Pittsburgh compound B for traumatic brain injury.</gtr:title><gtr:parentPublicationTitle>JAMA neurology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/274bdf7aacaeaabedd6556fa74b07bf9"><gtr:id>274bdf7aacaeaabedd6556fa74b07bf9</gtr:id><gtr:otherNames>Hong YT</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2168-6149</gtr:issn><gtr:outcomeId>54621f3950ae88.33839433</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B7479842-1FCC-4F9D-B4C7-5666E676D366</gtr:id><gtr:title>Glycogen Synthase Kinase 3 beta Inhibitor Scaffolds for PET Radiotracer Development</gtr:title><gtr:parentPublicationTitle>JOURNAL OF NUCLEAR MEDICINE</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/69e15452836300214f8c2e193db6d63d"><gtr:id>69e15452836300214f8c2e193db6d63d</gtr:id><gtr:otherNames>Mossine Andrew</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>56dd69b78e64d7.85620164</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>378D6BA5-B680-4516-9F9B-1D65B22FC1DD</gtr:id><gtr:title>Validation and quantification of [18F]altanserin binding in the rat brain using blood input and reference tissue modeling.</gtr:title><gtr:parentPublicationTitle>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0271-678X</gtr:issn><gtr:outcomeId>56dd67533e6616.79224748</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>5CC10EED-E204-48E4-B955-68EFDF22B608</gtr:id><gtr:title>A simple, rapid procedure for nucleophilic radiosynthesis of aliphatic [18F]trifluoromethyl groups.</gtr:title><gtr:parentPublicationTitle>Chemical communications (Cambridge, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1359-7345</gtr:issn><gtr:outcomeId>56dd675377bee1.82422819</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>903BE6CD-AE33-438F-BFC6-07214E3FDA43</gtr:id><gtr:title>Radiosynthesis and characterization of astemizole derivatives as lead compounds toward PET imaging of t-pathology</gtr:title><gtr:parentPublicationTitle>MedChemComm</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/314bc8a765e3a90c82b4212ea32bf536"><gtr:id>314bc8a765e3a90c82b4212ea32bf536</gtr:id><gtr:otherNames>Riss P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>m7UyvbCuWim</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3669ECD8-928C-4E54-BD93-359180FF65F8</gtr:id><gtr:title>Direct, nucleophilic radiosynthesis of [18F]trifluoroalkyl tosylates: improved labelling procedures.</gtr:title><gtr:parentPublicationTitle>Organic &amp; biomolecular chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1477-0520</gtr:issn><gtr:outcomeId>pm_16278_28_22833145</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3DEE047F-838F-41ED-920B-5AC2B8470126</gtr:id><gtr:title>Radiosynthesis and preliminary in vivo studies with [11C]SB216763: The first brain penetrative PET tracer for imaging of glycogen synthase kinase-3 (GSK-3)</gtr:title><gtr:parentPublicationTitle>Soceity of Nuclear Medicine and Molecular Imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1ae13520e57e23d06b3a3f17fa892406"><gtr:id>1ae13520e57e23d06b3a3f17fa892406</gtr:id><gtr:otherNames>Li Li</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:outcomeId>TtSuWTUey3G</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>79E0F9ED-63D5-4233-B4CB-B6F628F31609</gtr:id><gtr:title>Probing small molecule binding to amyloid fibrils.</gtr:title><gtr:parentPublicationTitle>Physical chemistry chemical physics : PCCP</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/41e28ad45f63b11e57e4bed174a7ddcb"><gtr:id>41e28ad45f63b11e57e4bed174a7ddcb</gtr:id><gtr:otherNames>Buell AK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1463-9076</gtr:issn><gtr:outcomeId>MhnBBvHJAaj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC08EB2B-B5B5-46FF-9056-6EA883A7B7E5</gtr:id><gtr:title>Orbitofrontal dopamine depletion upregulates caudate dopamine and alters behavior via changes in reinforcement sensitivity.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5d3ae7b0f559bda4fc815311855c0c45"><gtr:id>5d3ae7b0f559bda4fc815311855c0c45</gtr:id><gtr:otherNames>Clarke HF</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn><gtr:outcomeId>56dd67529b3937.58914085</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D9EC48F5-1228-4189-BE32-39A52E76FA47</gtr:id><gtr:title>Cu(I)-catalyzed (11)C carboxylation of boronic acid esters: a rapid and convenient entry to (11)C-labeled carboxylic acids, esters, and amides.</gtr:title><gtr:parentPublicationTitle>Angewandte Chemie (International ed. in English)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1433-7851</gtr:issn><gtr:outcomeId>pm_16278_28_22308017</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FE5F30F5-5BDE-4430-94F6-18D118CE0BA5</gtr:id><gtr:title>Translating positron emission tomography studies in animals to stimulant addiction: promises and pitfalls.</gtr:title><gtr:parentPublicationTitle>Current opinion in neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a204b8a3d47fba451af19560ec2abf6"><gtr:id>1a204b8a3d47fba451af19560ec2abf6</gtr:id><gtr:otherNames>Caprioli D</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0959-4388</gtr:issn><gtr:outcomeId>pm_16278_28_23664005</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>816715F0-E116-42A3-BF70-C7DAA38F4BD3</gtr:id><gtr:title>Synthesis and evaluation of 18F-FE-PEO in rodents: an 18F-labeled full agonist for opioid receptor imaging.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn><gtr:outcomeId>ihoLqQ8hVFb</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2B09B19D-62E3-4F45-9D8C-B39E976E460F</gtr:id><gtr:title>Characterisation of [&amp;sup1;&amp;sup1;C]PR04.MZ in Papio anubis baboon: a selective high-affinity radioligand for quantitative imaging of the dopamine transporter.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9f97b77c7d2fd486349ce8c01bd73e8b"><gtr:id>9f97b77c7d2fd486349ce8c01bd73e8b</gtr:id><gtr:otherNames>Riss PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>GBHanCBdgo4</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7147AFD4-C8EA-4F48-A829-C25333C14368</gtr:id><gtr:title>Behavior of Supramolecular Assemblies of Radiometal-Filled and Fluorescent Carbon Nanocapsules In&amp;nbsp;Vitro and In&amp;nbsp;Vivo</gtr:title><gtr:parentPublicationTitle>Chem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ef10dee2f07b0b90156ff3ec25fc751a"><gtr:id>ef10dee2f07b0b90156ff3ec25fc751a</gtr:id><gtr:otherNames>Ge H</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2451-9294</gtr:issn><gtr:outcomeId>5aa10ff208e231.05237600</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5FD639C-E313-4539-A7B3-6B394A15ACF7</gtr:id><gtr:title>Applications of positron emission tomography in animal models of neurological and neuropsychiatric disorders.</gtr:title><gtr:parentPublicationTitle>Neuroscience and biobehavioral reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/54cbeb0a12b195b78bcf0572ae0cfe39"><gtr:id>54cbeb0a12b195b78bcf0572ae0cfe39</gtr:id><gtr:otherNames>Virdee K</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0149-7634</gtr:issn><gtr:outcomeId>pm_16278_28_22342372</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B15C9AA-C06E-4633-98E0-7FC8C45AD610</gtr:id><gtr:title>No carrier-added nucleophilic aromatic radiofluorination using solid phase supported arenediazonium sulfonates and 1-(aryldiazenyl)piperazines</gtr:title><gtr:parentPublicationTitle>Tetrahedron Letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/314bc8a765e3a90c82b4212ea32bf536"><gtr:id>314bc8a765e3a90c82b4212ea32bf536</gtr:id><gtr:otherNames>Riss P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>doi_55f98598524cb8af</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0900903</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>3C193D18-12BD-4B15-8347-037BA623E0FF</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Mental Health</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>89AE580F-2437-4540-9640-37005C968E67</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.1  Discovery and preclinical testing of markers and technologies</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>